Benzocaine is known to cause a serious blood condition known as methemoglobinemia (MetHb) both in adults as well as in children. Currently, all benzocaine-containing products (except lozenges) marketed in Canada are required to carry a warning regarding the risk of MetHb.
In 2018, Health Canada stopped authorizing benzocaine-containing products for use in children under 2 years of age because the serious risk of MetHb is greater than the benefit, especially since children under 2 years old may be unable to communicate that they are experiencing symptoms of MetHb such as weakness, confusion, headache, and/or difficulty breathing.
Health Canada is concerned that children under 2 years of age may still be given benzocaine-containing products despite previous warnings concerning this health risk.
Products affected
Over-the-counter benzocaine-containing products.
Background information
Over-the-counter (OTC) benzocaine-containing products are available in different formulations (gels, sprays, swabs, liquids, lotions, creams and lozenges) and are commonly used for the temporary relief of minor pain due to a variety of conditions, including, sore throat, toothache, canker sores, and mouth or gum irritation. OTC benzocaine-containing products have also been used to treat teething pain.
Benzocaine has been associated with methemoglobinemia (MetHb), a serious blood condition that reduces the ability of red blood cells to deliver oxygen throughout the body. Health Canada previously communicated on this safety issue in
April 2012,
April 2011 and
November 2006.
In 2012, Health Canada requested manufacturers of all benzocaine-containing products (except lozenges) to add new warnings regarding the risk of MetHb to the packaging and labelling. The warnings included a statement to consult a healthcare professional prior to using these products in children less than 2 years of age.
The US Food and Drug Administration issued a
Drug Safety Communication (DSC) in 2018 warning about the rare, but serious, potentially fatal adverse reaction MetHb with the use of benzocaine products (gels, liquids and sprays) applied to the gums or mouth, or used for medical procedures. The DSC warned that these products should no longer be used in infants and children less than 2 years of age due to an unfavourable benefit-risk profile, and to use caution when used in older children and adults.
In 2018, Health Canada decided to stop authorizing benzocaine-containing products for children under 2 years of age because:
-
the benefits of these products do not outweigh the serious risk of MetHb in children younger than 2 years of age.
-
the warnings for MetHb directed to parents/caregivers are insufficient, as children under 2 years of age may be unable to communicate that they are experiencing symptoms of MetHb like weakness, confusion, headache, and/or difficulty breathing.
Most of the manufacturers of benzocaine-containing products, which were licensed prior to 2018, have added the warnings regarding the risk of MetHb and stopped promoting the use of these products in children younger than 2 years of age. In August 2020, Health Canada issued stop-sales for the few existing benzocaine-containing products that had not updated their labelling.
Despite these measures, Health Canada is concerned that healthcare professionals and parents/caregivers may be continuing to recommend or use benzocaine products in this age group given its long history of use as a teething pain reliever.